SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001484565

SLNO

SOLENO THERAPEUTICS INC
—
12-mo target$53.00 (-0.0%)
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)25 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SLNO right now — valuation, ownership and activity at a glance.
Inst. Holders
50 funds
Inst. Value
$1.3B
Inst. Activity
0 buys / 25 sells
SEC Reports
10
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 2, 2026 other
Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — EXIT
0 shares ($0.00)
Jun 11, 2026 SEC
15 institutional investors accumulated positions in SLNO during Q3 2024, with Pictet Asset Management ($29.1M) and Inves
INST-CLUSTER — Impact 6/10
Jun 11, 2026 SEC
Six institutional investors accumulated $883.9M in SLNO (net +$345.5M) while four reduced holdings by -$139.4M. The buyi
INST-CLUSTER — Impact 4/10
May 28, 2026 SEC
Soleno Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g) and suspend reporting obliga
15-12G — Impact 8/10
May 18, 2026 Insider
Anish Bhatnagar disposed of 131,400 shares
CHIEF EXECUTIVE OFFICER
May 18, 2026 Insider
Anish Bhatnagar disposed of 115,600 shares
CHIEF EXECUTIVE OFFICER
Analyst ratings buy % -100.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
DateFirmActionRatingFirm rating
Apr 17, 2026Wells FargoDOWNGRADEEqual-Weight 54%
Apr 8, 2026HC Wainwright & Co.DOWNGRADENeutral 43%
Apr 7, 2026TD CowenDOWNGRADEHold 56%
Apr 7, 2026Wolfe ResearchDOWNGRADEPeer Perform 52%
Apr 6, 2026Cantor FitzgeraldDOWNGRADENeutral 49%
Mar 18, 2026OppenheimerMAINTAINOutperform 52%
Mar 4, 2026HC Wainwright & Co.MAINTAINBuy 43%
Feb 27, 2026Wells FargoMAINTAINOverweight 54%
Feb 26, 2026TD CowenMAINTAINBuy 56%
Jan 20, 2026Wells FargoMAINTAINOverweight 54%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 20260013120%
Aug 1, 20260013120%
Jul 1, 20260013120%
Jun 1, 20260013120%
May 1, 20260013120%
Apr 1, 202671110095%
Mar 1, 202671110095%
Feb 1, 202671110095%
Price targets
Where 5 covering analysts think SLNO trades over the next 12 months.
$53.00 -0.0% upside Hold
Current$53.01 Low$53.00 Median$53.00 High$53.00 5 analysts
$53.00$53.00
Analyst rating Hold· 3.0/5 as of Jul 18, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
Recent posts
wallstreetbets Neutral 5mo ago
SLNO- Soleno Therapeutic acquisition by Neurocrine, for $53/Per share, is there any other companies can bid higher to acquire Soleno.
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 4 bullish, 3 bearish, 1 mixed, 2 neutral · avg impact 6.0/10.
BULLISHINST-CLUSTER6/10
15 institutional investors accumulated positions in SLNO during Q3 2024, with Pictet Asset Managemen
Jun 11, 2026
MIXEDINST-CLUSTER4/10
Six institutional investors accumulated $883.9M in SLNO (net +$345.5M) while four reduced holdings b
Jun 11, 2026
BEARISH15-12G8/10
Soleno Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g) and susp
May 28, 2026
BEARISHEFFECT5/10
Soleno Therapeutics' shelf registration statement on Form S-3 (File No. 333-275120) was declared eff
May 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 2, 2026
other
Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of
Aug 6, 2026
earnings_calendar
SLNO Q2 2026 Earnings Scheduled — 2026-08-06
May 19, 2026
ftd
FTD: SLNO — 64,409 shares ($3.4M) failed to deliver
Settlement: 20260519, Price: $53.01, FTD Value: $3,414,321.09, SOLENO THERAPEUTICS INC COM PA
May 18, 2026
ftd
FTD: SLNO — 64,482 shares ($3.4M) failed to deliver
Settlement: 20260518, Price: $53.01, FTD Value: $3,418,190.82, SOLENO THERAPEUTICS INC COM PA
May 15, 2026
ftd
FTD: SLNO — 194,854 shares ($10.3M) failed to deliver
Settlement: 20260515, Price: $52.99, FTD Value: $10,325,313.46, SOLENO THERAPEUTICS INC COM PA
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Next Q$1.06$0.78–$1.55125.5%+0.0%0↑ 4↓$0.1B8
Current Q$0.93$0.78–$1.261137.5%-0.4%0↑ 3↓$0.1B8
Next FY$6.06$3.61–$9.9255.6%-3.6%0↑ 4↓$0.7B7
Current FY$3.89$2.69–$5.55897.8%-1.4%0↑ 4↓$0.5B8
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$0.934—
7d ago$0.938-0.004
30d ago$0.938-0.004
60d ago$0.939-0.005
90d ago$0.980-0.046
Institutional ownership
Which big funds own SLNO (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.3B total value (39,851,050 shares) as of 2026-Q1. Top holders: NOMURA, FMR, WELLINGTON. Net buying activity: 18 institutions added/increased vs 7 reduced.
Top holders — 2026-Q1
FundSharesValue% TrackedLast move
NOMURA ASSET MANAGEMENT CO LTD0$0.000.0%—
FMR LLC5,788,410$193.8M14.5%EXIT -100.0%
WELLINGTON MANAGEMENT GROUP LLP4,426,781$148.2M11.1%EXIT -100.0%
BlackRock, Inc.3,742,774$125.3M9.4%EXIT -100.0%
STATE STREET CORP2,680,802$89.8M6.7%EXIT -100.0%
Avoro Capital Advisors LLC2,300,000$77.0M5.8%EXIT -100.0%
VANGUARD CAPITAL MANAGEMENT LLC2,153,218$72.1M5.4%EXIT -100.0%
Polar Capital Holdings Plc1,698,855$56.9M4.3%EXIT -100.0%
GEODE CAPITAL MANAGEMENT, LLC1,237,550$41.4M3.1%EXIT -100.0%
Caption Management, LLC1,169,200$39.1M2.9%EXIT -100.0%
Recent position changes
FundActionPrevCurrentChangeValue
GEODE CAPITAL MANAGEMENT, LLCEXIT1,237,5500-100.0%$0.00
CITADEL ADVISORS LLCEXIT386,5450-100.0%$0.00
Avoro Capital Advisors LLCEXIT2,300,0000-100.0%$0.00
Hood River Capital Management LLCEXIT623,4210-100.0%$0.00
Caption Management, LLCEXIT420,1430-100.0%$0.00
Woodline Partners LPEXIT1,112,1040-100.0%$0.00
Polar Capital Holdings PlcEXIT1,698,8550-100.0%$0.00
Qube Research & Technologies LtdEXIT483,8840-100.0%$0.00
SCHRODER INVESTMENT MANAGEMENT GROUPEXIT648,8270-100.0%$0.00
BNP PARIBAS FINANCIAL MARKETSEXIT432,5350-100.0%$0.00
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
DateInsiderTitleTypeSharesPriceValue
May 18, 2026Anish BhatnagarCHIEF EXECUTIVE OFFICERD131,400——
May 18, 2026Anish BhatnagarCHIEF EXECUTIVE OFFICERD115,600——
May 18, 2026Anish BhatnagarCHIEF EXECUTIVE OFFICERD100,000——
May 18, 2026Anish BhatnagarCHIEF EXECUTIVE OFFICERD200,753——
May 18, 2026Anish BhatnagarCHIEF EXECUTIVE OFFICERD52,709——
May 18, 2026Anish BhatnagarCHIEF EXECUTIVE OFFICERD73,333——
May 18, 2026Anish BhatnagarCHIEF EXECUTIVE OFFICERD8,473——
May 18, 2026Anish BhatnagarCHIEF EXECUTIVE OFFICERD35,000——
May 18, 2026Anish BhatnagarCHIEF EXECUTIVE OFFICERD23,332——
May 18, 2026Anish BhatnagarCHIEF EXECUTIVE OFFICERD60——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SLNO.
Shares short
4,405,832
Settlement May 15, 2026
Change vs prior
-32.5%
Semi-monthly cycle
Days to cover
2.3
At avg daily volume
All SLNO filing & press-release reports (10)